Core Viewpoint - A class action lawsuit has been filed against Replimune Group, Inc. concerning allegations of securities fraud and unlawful business practices related to the company's recent FDA response regarding its drug application [1][2]. Group 1: Lawsuit Details - The class action lawsuit is focused on whether Replimune and certain officers or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until September 22, 2025, to request to be appointed as Lead Plaintiff if they purchased Replimune securities during the Class Period [2]. Group 2: FDA Response and Stock Impact - On July 22, 2025, Replimune received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for RP1 in combination with nivolumab for advanced melanoma [4]. - The CRL indicated that the FDA could not approve the application in its current form, citing inadequacies in the IGNYTE trial and issues with the patient population's heterogeneity [4]. - Following the announcement, Replimune's stock price fell by $9.52 per share, or 77.24%, closing at $2.81 per share on the same day [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Replimune Group, Inc. regarding a class action lawsuit due to alleged misleading statements related to the IGNYTE trial [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from November 22, 2024, to July 21, 2025 [1]. - The complaint claims that defendants overstated the IGNYTE trial's prospects, leading to the FDA deeming the trial inadequate [1]. - It is alleged that the defendants' statements about Replimune's business and operations were materially false and misleading [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 22, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's status [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Replimune Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Replimune securities class action is from November 22, 2024, to July 21, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members [3]. Group 2: Case Background - The lawsuit alleges that defendants made materially false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [5]. - The misleading statements resulted in damages to investors when the true details about Replimune's business and operations were revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [4].

Core Viewpoint - A class action securities lawsuit has been filed against Replimune Group, Inc. due to alleged securities fraud affecting investors between November 22, 2024, and July 21, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that defendants made false statements regarding the IGNYTE trial's prospects, which were known to be materially inadequate by the defendants [2]. - The lawsuit claims that the defendants' statements about Replimune's business and operations were materially false and misleading, lacking a reasonable basis [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff, although participation does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Replimune Group, Inc. due to alleged securities fraud affecting investors between November 22, 2024, and July 21, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that defendants made false statements regarding the IGNYTE trial, overstating its prospects despite known material issues, leading to the FDA deeming the trial inadequate [2]. - Defendants' statements about Replimune's business and operations were claimed to be materially false and misleading, lacking a reasonable basis at all relevant times [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a 20-year history of securing hundreds of millions for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Replimune Group, Inc. about a class action lawsuit due to alleged misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [1][3]. Group 1: Allegations and Class Period - The class period for the lawsuit is from November 22, 2024, to July 21, 2025 [3]. - Allegations include that defendants overstated the IGNYTE trial's prospects and failed to disclose material issues, leading to misleading statements about Replimune's business and operations [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 22, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. due to allegations of violations of federal securities laws related to misleading statements about the IGNYTE trial and its FDA approval process [3][5][7] Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $50,000 in Replimune between November 22, 2024, and July 21, 2025, to discuss their legal options [1] - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [3][8] - The complaint alleges that Replimune and its executives made false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [5][7] Group 2: Impact of FDA Response - On July 22, 2025, Replimune received a Complete Response Letter (CRL) from the FDA, indicating that the application for RP1 was not approved in its current form due to inadequacies in the IGNYTE trial [6][7] - Following the announcement of the CRL, Replimune's stock price fell over 73% during intraday trading on the same day [7] Group 3: Firm Background and Contact Information - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4] - The firm is actively seeking information regarding Replimune's conduct from whistleblowers, former employees, and shareholders [9]

Core Viewpoint - A class action securities lawsuit has been filed against Replimune Group, Inc. due to alleged securities fraud affecting investors between November 22, 2024, and July 21, 2025 [1][2] Group 1: Lawsuit Details - The complaint alleges that defendants made false statements regarding the IGNYTE trial's prospects, which were known to be inadequate and poorly controlled by the FDA [2] - Defendants' statements about Replimune's business and operations were materially false and misleading, lacking a reasonable basis during the relevant time [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions for shareholders and being recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4]

Core Viewpoint - The Gross Law Firm is notifying shareholders of Replimune Group, Inc. about a class action lawsuit due to alleged misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [1][3]. Group 1: Allegations and Class Period - The class period for the lawsuit is from November 22, 2024, to July 21, 2025 [3]. - Allegations include that defendants overstated the IGNYTE trial's prospects and failed to disclose material issues, leading to misleading statements about Replimune's business and operations [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 22, 2025, to potentially be appointed as lead plaintiff [4]. - Registration allows shareholders to receive updates through a portfolio monitoring software regarding the case's status [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

Core Viewpoint - A securities class action lawsuit has been filed against Replimune Group, Inc. following a significant drop in its stock price after the FDA rejected its drug application for RP1, intended for advanced melanoma treatment [1][2]. Group 1: Lawsuit Details - The lawsuit, Jboor v. Replimune Group, Inc., seeks to represent investors who acquired Replimune securities between November 22, 2024, and July 21, 2025 [1][4]. - The lead plaintiff deadline for the lawsuit is set for September 22, 2025 [4]. Group 2: FDA Rejection and Market Reaction - Replimune's stock price plummeted by 77% on July 22, 2025, following the FDA's rejection of its application for RP1, which was communicated through a "complete response letter" [2][9]. - The FDA indicated that the IGNYTE trial was not well-designed or controlled, leading to doubts about the drug's effectiveness [7][8]. Group 3: Allegations Against Replimune - The complaint alleges that Replimune made false and misleading statements regarding the IGNYTE study, overstating its prospects and failing to disclose the trial's inadequacies [6][5]. - The FDA's findings highlighted significant issues with the trial's patient population diversity, complicating the interpretation of results [8][7]. Group 4: Investigation and Whistleblower Information - Hagens Berman is investigating whether Replimune misled investors about the IGNYTE trial design and data [3][9]. - Whistleblowers with non-public information regarding Replimune are encouraged to assist in the investigation, with potential rewards under the SEC Whistleblower program [11].